Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report

Table 1 Laboratory values and clinical symptoms

	Before treatment	After four cycles of DLd	3 months after ASCT
Serum VEGF (pg/mL)	5000	826	212
Hematologic	1.81 g/dL M-spike in serum electrophoresis	0.50 g/dL M-spike in serum electrophoresis	Negative M-spike in serum electrophoresis, detectable M-protein in serum immunofixation
PET–CT	FDG-avid lesion SUV_max = 6.91	FDG-avid lesion SUV_max = 4.04	FDG-avid lesion SUV_max = 2.22
ONLS	5	1	0
MCV of median nerve (m/second)	36.1	36.6	43.5
Ascites	Grade 2	Grade 1	Absent
Edema	Grade 1	Absent	Absent
Papilledema	Grade 1	Grade 1	Absent
DLCO (%)	53	68.4	94.0
ECOG PS	2	1	0

DLd, daratumumab, lenalidomide, and dexamethasone; ASCT, autologous stem cell transplantation; VEGF, vascular endothelial growth factor; M-spike, monoclonal spike; M-protein, monoclonal protein; PET–CT, positron emission tomography-computed tomography; FDG, fluorodeoxyglucose; SUV, standardized uptake value; ONLS, Overall Neuropathy Limitations Scale; MCV, motor nerve conduction velocity; DLCO, diffusing capacity for carbon monoxide; ECOG PS, Eastern Cooperative Oncology Group performance status.

ISSN: 1752-1947